Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ADMA Biologics (ADMA)

ADMA Biologics Q2 revenue rises 14% to $122.0 million; $300 million credit deal

Positive Impact 3 of 5 earnings Written later

ADMA Biologics reported second-quarter 2025 revenue of $122.0 million, up 14%, and GAAP net income of $34.2 million, up from $32.1 million a year earlier. On August 5, 2025, the company entered a $300 million senior secured credit agreement led by JPMorgan Chase Bank, N.A., and used it to repay its prior Ares Capital Corporation facility in full. The company also reaffirmed its full-year 2025 and 2026 guidance.

Key points

  • Q2 2025 total revenue was $122.0 million, up from $107.2 million; diluted EPS was $0.14 versus $0.13.
  • Credit Agreement dated August 5, 2025: $75 million term loan and $225 million revolver, both maturing August 5, 2028.
  • Proceeds repaid the Ares Capital Corporation credit facility in full, with a $1.2 million loss on extinguishment of debt recorded in Q2.
  • FY 2025 revenue guidance of more than $500 million and Adjusted EBITDA guidance of more than $235 million were reaffirmed.

The filing

CompanyADMA Biologics (ADMA)
Form8-K, current report
Filed with the SECAug 6, 2025, 4:11 PM ET
Accession number0001140361-25-029143

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.02 Results of Operations2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.